Production of therapeutic levels of human FIX-R338L by engineered B cells using GMP-compatible medium

B cells can differentiate into plasmablast and plasma cells, capable of producing antibodies for decades. Gene editing using zinc-finger nucleases (ZFN) enables the engineering of B cells capable of secreting sustained and high levels of therapeutic proteins. In this study, we established an advance...

Descripción completa

Detalles Bibliográficos
Autores principales: David, Marion, Monteferrario, Davide, Saviane, Gaëlle, Jeanneau, Caroline, Marchetti, Irène, Dupont, Coralie F., Dumont, Céline, Fontenot, Jason D., Rosa, Maurus de la, Fenard, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543988/
https://www.ncbi.nlm.nih.gov/pubmed/37790246
http://dx.doi.org/10.1016/j.omtm.2023.101111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543988/
https://www.ncbi.nlm.nih.gov/pubmed/37790246
http://dx.doi.org/10.1016/j.omtm.2023.101111

Ejemplares similares